Business Context and Reporting Period
This Form 8-K filing by Akebia Therapeutics, Inc. (AKBA) reports corporate governance changes effective April 1, 2026. The report date is March 27, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition and director compensation.
Material Changes
- Director Resignation: Steven C. Gilman, Ph.D., resigned from the Board effective April 1, 2026. The resignation is not due to any disagreement with the Company.
- Director Election: Philip J. Vickers, Ph.D., was elected as a Class I director effective April 1, 2026, with a term expiring at the 2027 annual meeting.
- Committee Appointments: Dr. Vickers was appointed to the Compensation Committee and the Research & Development Committee.
Guidance, Outlook, and Compensation Details
The filing details the compensation package for the newly elected director, Dr. Vickers, under the Company's Non-Employee Director Compensation Program:
- Cash Retainers: $50,000 annual Board retainer, $7,500 for the Compensation Committee, and $5,000 for the Research & Development Committee.
- Initial Equity Grant: On April 1, 2026, Dr. Vickers received 214,400 stock options at an exercise price of $1.41 per share.
- Future Equity Grants: Commencing at the 2027 annual meeting, Dr. Vickers is eligible for an annual grant of 53,600 options and 35,700 restricted stock units.
- Indemnification: Dr. Vickers is entitled to the same indemnification rights as other non-employee directors.
The filing does not contain management commentary on business outlook, risks, or contingencies beyond the standard governance disclosures.
Investor Verification Checklist
- Verify the effective date of Dr. Gilman's resignation and Dr. Vickers' election (April 1, 2026).
- Confirm the exercise price of the initial option grant to Dr. Vickers ($1.41 per share).
- Review the attached Press Release (Exhibit 99.1) for additional context on the board changes.
- Check the Company's latest 10-K or 10-Q for financial metrics, as this 8-K does not contain financial performance data.